Biopharma dealmaking continues to rise, but M&A values hold steady: PwC

[cafead]

via Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come to the same conclusion.

article source